Clearly, identification and characterization of a cell surface receptor for heparanase constitutes a most relevant challenge for progress in the field.
Clearly, identification of tumor-initiating stem cells (TISCs) in a pool of tumor cells is a pre-requisite for successful therapeutic targeting or direct elimination of such cells.
Clearly, identification of the molecular expression patterns of all ion channel and ion exchanger subtypes in myometrial cells of the uterus is essential (e.g. [107]), and marrying such data to precise electrophysiological, pharmacological and simulated profiles (even if initially this is in clonal cells), is required to furnish a complete biophysical characterization of normal uterine function.
Clearly, identification of new molecules involved in osteolytic bone metastasis will provide new therapeutics possibilities.
Clearly, identification strategies will need to be tailored for each intervention.
For more than a decade, mutagenicity tests have had a clearly defined role in the identification of potential human mutagens and an ancillary role in the identification of potential human carcinogens.
Clearly, receptor identification is a major goal in clarifying the role that these pathways play in vivo.
Clearly, the identification of an ever-increasing number of functions for p53 provokes the important question of how the final response of the cell is determined.
Clearly, an unambiguous identification of the OTI was not possible.
Clearly, the identification of nitrated proteins is an ongoing process, but it also highlights the need to develop an organelle-specific understanding of NO effects as, due to its reactivity, it is unlikely that ONOO− will move out of the plastids to nitrate cytoplasmic proteins.
